Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs188.27 M567 M1.13 B1.75 B1.32 B1.15 B979 MRecherche et développement1.37 B1.99 B3.29 B4.84 B4.54 B3.13 B2.92 BRésultat d'exploitation-763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B-3.41 BTotal des produits hors exploitation-53.84 M-65 M124 M323 M381 M365 M331 MCharges d'intérêts, nettes des intérêts capitalisés9.89 M17 M29 M38 M24 M3 M—Résultat hors exploitation, hors charges d'intérêts-57.65 M-53 M140 M409 M444 M370 M353 MRevenus/dépenses exceptionnels-6.08 M-29 M-45 M-124 M-87 M-8 M-22 MRésultat avant impôts-744.51 M13.29 B9.57 B-3.94 B-3.61 B-2.77 B-3.14 BPart des actionnaires dans le résultat———-35 M-52 M-8 M-2 MImpôts2.55 M1.08 B1.21 B772 M-46 M54 M56 MIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts——-28 M-7 M-60 M-77 M-81 MRésultat net avant activités abandonnées-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-3.19 BActivités abandonnées———————Résultat net-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-3.19 BAjustement de dilution0——————Dividendes privilégiés0——————Résultat net dilué revenant aux actionnaires ordinaires-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-3.19 BBénéfice par action de base (BPA de base)—30.3121.26-12.33-9.28-7.26-8.14Bénéfice par action dilué (BPA dilué)—28.2920.12-12.33-9.28-7.26-8.14Nombre moyen d'actions de base en circulation—403 M394 M382 M384 M389 M—Nombre d'actions en circulation après dilution—431 M416 M382 M384 M389 M—EBITDA-731.89 M13.53 B9.77 B-3.62 B-3.76 B-2.86 B-3.18 BEBIT-763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B-3.41 BCoût des ventes7.93 M2.62 B5.42 B4.69 B1.46 B868 M1.73 BAutres coûts des ventes——1.92 B2.34 B555 M315 M301 MAmortissements (flux de trésorerie)31.25 M232 M348 M617 M185 M211 M229 M
Moderna, Inc. - Common Stock
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.